Trial Profile
A Phase IIb Pilot Study to Assess the Efficacy, Safety, and Pharmacodynamics Effects of Pembrolizumab and BL-8040 in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Oct 2023 Status changed from active, no longer recruiting to completed.
- 11 Sep 2023 Status changed from suspended to active, no longer recruiting.
- 07 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 May 2023.